Compare Southwest Airlines Co (LUV) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Mesoblast Limited — how do they compare? Southwest Airlines Co trades at $48.82 (market cap $23.63B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Southwest Airlines Co is far larger — about 10.9× Mesoblast Limited's market cap, and Southwest Airlines Co pays a 1.49% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| LUV | MESO | |
|---|---|---|
Market Cap | $23.63B | $2.17B |
Sector | Industrials | Technology |
52-Week High | $54.80 | $20.96 |
52-Week Low | $29.06 | $12.88 |
Enterprise Value | $26.70B | $2.17B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $48.28, up 0.42% today, with a neutral technical signal and mixed earnings history. Recent Q1 2026 EPS missed expectations, but Q4 2025 and Q3 2025 beat. Financials show modest revenue growth to $28.06B in 2025, but net income margin is thin at 2.83%. Analyst consensus is mixed with 42% buy, 47% hold, and 11% sell ratings, and a $52.47 price target implies potential upside. Key news highlights Q2 2026 earnings due July 23, 2026, amid fuel cost volatility and travel demand resilience.
LUV presents a cautious opportunity with upside to the consensus target, supported by operational improvements and sector tailwinds, but risks from fuel price swings, execution challenges, and thin margins warrant careful monitoring. The stock's valuation at a P/E of 32.05 appears elevated relative to earnings growth, requiring strong future performance to justify current levels.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
